CMT Research Foundation
  • Home
  • What is CMT?
    • Types of CMT
      • What is CMT1?
      • What is CMT2?
      • What is CMT4?
      • What is CMTX?
    • Treatments for CMT
    • Signs & Symptoms
    • Video Series
      • Everything You Need to Know in Five Minutes
      • Demystifying the Drug Development Process
      • How Patients Can Change the Pace of Drug Development
      • How We Get from Today to FDA-Approved Treatments
      • Conversations with Researchers Working in CMT
  • Who We Are
    • Overview
    • Staff
    • Board of Directors
    • Scientific Advisory Board
    • Volunteers
    • Transparency
  • Research
    • Overview
    • Research Pipeline
    • Research News
    • Research We Fund
    • Clinical Trials
    • CMTRF Research Priorities
    • Apply for Funding for CMT Research Grants
  • News & Events
    • News & Opinion
  • Contact Us
  • Donate
Select Page

Susan B. Canavari Joins CMT Research Foundation Board of Directors

Sep 21, 2020 | News, Press Releases

Deeply Experienced Brand Marketer to Help Increase Awareness of CMT and Accelerate Research ATLANTA (September 21, 2020) The CMT Research Foundation, a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease during our lifetime,...

CMT Research Foundation Adds New Chief Operating Officer and Chief Scientific Officer

Aug 17, 2020 | News, Press Releases

The CMT Research Foundation Adds Erich Fasnacht as Chief Operating Officer and Keith Fargo as Chief Scientific Officer Reinforces CMTRF’s Reputation as Preeminent Experts in CMT Research ATLANTA (August 17, 2020) The CMT Research Foundation (CMTRF), a nonprofit...

CMT Ends with Me: My Painful Decision Not to Become a Mother

May 7, 2020 | Press Releases, Stories

By: Diane, CMT Patient I’d give you my feet if I could. That’s what my strong, stoic mother told me as she struggled to watch me walk as a teenager. I was a natural athlete growing up. I loved running and excelled at it. One day while running, I blew out my ankle....

Milestone 2 Completed for CMT1A Project from Cyprus Institute of Neurology and Genetics

Feb 12, 2020 | CMT Research Updates, CMTRF Funded Research, Drug Development, Press Releases, Research news

In February 2020, Dr. Kleopa completed milestone 2 of the 24-month project and the results continue to be encouraging.   The goal during this 6-12 month period of the project was to further optimize the amount of PMP22 gene silencing in a mouse model of CMT1A.    Dr....

Creating multiple opportunities for success in CMT 1A

Feb 12, 2020 | CMT Research Updates, CMTRF Funded Research, Drug Development, Gene Therapy, Press Releases

By Grace Pavlath, PhD By now you’ve likely heard that CMTRF is funding three genetic-based projects focused on therapy development for CMT1A:    DTx Pharma,  Shift Pharma and  Cyprus Institute of Neurology and Genetics.  Funding multiple complementary approaches gives...

CMT Research Foundation Funds Shift Pharmaceuticals to Advance Search for CMT1A Treatment

Jan 30, 2020 | CMT Research Updates, CMTRF Funded Research, Drug Development, Press Releases, Research news

Shift to Develop and Analyze Novel Series of Drugs Designed to Control Expression of PMP22 Gene The CMT Research Foundation (CMTRF), a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, today announced it has partnered with...
« Older Entries

Search Articles

Categories

  • About CMT
  • CMT Research Updates
  • CMTRF Funded Research
  • Drug Development
  • Gene Therapy
  • Life with CMT
  • News
  • Press Releases
  • Research news
  • Small Molecule Therapies
  • Stories
  • Therapy Types
  • Uncategorized

RSS Important Research News Announcements

  • Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study January 9, 2021
  • Epigenetic Regulation of CMT: A Lesson from Drosophila Models January 7, 2021
  • Clinical features of homozygous FIG4-p.Ile41Thr Charcot-Marie-Tooth 4J patients January 6, 2021
  • Aberrant Splicing in GJB1 and the Relevance of 5′ UTR in CMTX1 Pathogenesis December 28, 2020
  • Plasma neurofilament light chain as a potential biomarker in Charcot-Marie-Tooth disease December 20, 2020
  • Neurogene adds another $115M to the pot for trials for its gene therapies, including its CMT4J program December 18, 2020
  • More Than Hope: An Action Plan to End CMT December 18, 2020
  • Aminoacyl-tRNA synthetases in Charcot-Marie-Tooth disease: a gain or a loss? November 26, 2020
  • The expanding genetic landscape of hereditary motor neuropathies November 19, 2020
  • Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Type 1A (CMT1A) November 19, 2020
©2018 CMT Research Foundation | Privacy Policy
This website uses cookies to improve your experience. Full details can be found here. Cookie settingsACCEPT REJECT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT